

# Magda Siskova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1933869/publications.pdf>

Version: 2024-02-01

28  
papers

463  
citations

933447

10  
h-index

713466

21  
g-index

32  
all docs

32  
docs citations

32  
times ranked

635  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. <i>British Journal of Haematology</i> , 1998, 100, 304-309.   | 2.5 | 192       |
| 2  | Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2009, 33, 340-343.  | 0.8 | 41        |
| 3  | Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome. <i>Hemoglobin</i> , 2011, 35, 217-227.  | 0.8 | 31        |
| 4  | Prognostic significance of del(20q) in patients with hematological malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 188-192.   | 1.0 | 30        |
| 5  | Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. <i>Leukemia Research</i> , 2016, 42, 7-12.                  | 0.8 | 27        |
| 6  | High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. <i>European Journal of Haematology</i> , 2015, 95, 27-34.  | 2.2 | 26        |
| 7  | Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis. <i>Leukemia Research</i> , 2014, 38, 537-544.  | 0.8 | 24        |
| 8  | Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. <i>Leukemia Research</i> , 2007, 31, 39-47.  | 0.8 | 20        |
| 9  | Structural aberrations of chromosome 7 revealed by a combination of molecular cytogenetic techniques in myeloid malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 10-16.  | 1.0 | 17        |
| 10 | Transcription factors Fli1 and EKLf in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia. <i>Annals of Hematology</i> , 2013, 92, 11-18.   | 1.8 | 16        |
| 11 | DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts. <i>Human Molecular Genetics</i> , 2008, 17, 2144-2149.   | 2.9 | 10        |
| 12 | Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 43, 51-57.   | 0.8 | 8         |
| 13 | Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery. <i>Leukemia Research</i> , 2009, 33, 1567-1569.  | 0.8 | 5         |
| 14 | Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS). <i>Journal of Thrombosis and Haemostasis</i> , 2008, 8, 1087-1091.  | 0.8 | 5         |
| 15 | Lenalidomide treatment in lower risk myelodysplastic syndromes: The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in). <i>Journal of Thrombosis and Haemostasis</i> , 2011, 11, 1073-1077. | 0.8 | 5         |
| 16 | Accumulation of homoplasmic mtDNA point mutations in erythroblasts isolated from the bone marrow of patients with refractory anemia with ring sideroblasts (RARS). <i>Mitochondrion</i> , 2004, 4, 321-329.  | 3.4 | 2         |
| 17 | Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites. <i>Leukemia Research</i> , 2012, 36, e125-e127.   | 0.8 | 1         |
| 18 | Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 396-405.  | 2.8 | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome.. Blood, 2009, 114, 2788-2788.   | 1.4 | 1         |
| 20 | Combination of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience.. Journal of Clinical Oncology, 2011, 29, e14152-e14152.                            | 1.6 | 1         |
| 21 | P081 The questions on megakaryopoiesis in MDS patients with del(5q). Leukemia Research, 2009, 33, S105.   | 0.8 | 0         |
| 22 | P-202 MDS development risk in CLL patients with prolonged cytopenia after fludarabine, cyclophosphamide and rituximab (FCR) rÃ©gime. Leukemia Research, 2013, 37, S114-S115.                                      | 0.8 | 0         |
| 23 | P-231 The role of Fli1 and p53 for the effective megakaryopoiesis in 5q-syndrome. Leukemia Research, 2013, 37, S127.  | 0.8 | 0         |
| 24 | Molecular Cytogenetic Studies of Complex Karyotypes in Myelodysplastic Syndromes (MDS): Conventional Cytogenetics, FISH and Multiplex FISH (mFISH/mBAND). Blood, 2008, 112, 5075-5075.                            | 1.4 | 0         |
| 25 | Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q).. Blood, 2009, 114, 1623-1623.  | 1.4 | 0         |
| 26 | Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1790-1790. | 1.4 | 0         |
| 27 | High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide. Blood, 2013, 122, 1529-1529.   | 1.4 | 0         |
| 28 | Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes. Blood, 2014, 124, 859-859.  | 1.4 | 0         |